Cypress Capital’s Editas Medicine EDIT Stock Holding History

Cypress Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-400	Closed	-$1.87K	–	163
2024 Q2	$1.87K	Buy	+400	New	+$2.26K	﹤0.01%	293

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cypress Capital's EDIT Position: Q3 2024 in Review

Cypress Capital sold out of Editas Medicine (EDIT) in Q3 2024, closing a stake of 400 shares — an estimated $1.87K sold.

Cypress Capital first reported a position in EDIT in Q2 2024 and held it in 1 quarter. The position peaked at $1.87K in Q2 2024. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

Cypress Capital reported no remaining Editas Medicine position as of Q3 2024 after selling out during the quarter.
Cypress Capital sold 400 Editas Medicine shares in Q3 2024, an estimated $1.87K.
Cypress Capital first reported a position in Editas Medicine in Q2 2024 and held it in 1 quarter.
Cypress Capital's Editas Medicine position peaked at $1.87K in Q2 2024.
229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.